Logo

American Heart Association

  82
  0


Final ID: Su4011

The Artificial Intelligence-Derived Electrocardiographic Age Gap is Associated with Adverse Clinical Outcomes in Cardiac Laminopathy

Abstract Body (Do not enter title and authors here): Background: Disease-causative variants in LMNA-encoded lamin A/C cause the laminopathies, a heterogeneous group of diseases variably resulting in arrhythmogenic/dilated cardiomyopathy (ACM/DCM), lipodystrophy, muscular dystrophy, and progeria. The artificial intelligence (AI)-derived electrocardiographic age gap (AI-EAG), determined by the discrepancy between a patient’s artificial AI-enabled electrocardiogram (ECG) predicted biological age versus their chronological age, is accelerated in laminopathy. Thus, we sought to determine if the AI-EAG serves as a prognostic marker in patients with cardiac laminopathy.
Methods: Retrospective analysis of 1,049 genotype-positive patients with genetic ACM/DCM was used to identify those with pathogenic/likely pathogenic (P/LP) variants in LMNA. After the exclusion of those who lacked a 12-lead ECG while in sinus rhythm, a previously trained AI-ECG age algorithm was used to determine the AI-EAG by subtracting the patient’s chronological age from the AI-ECG derived biological age. The AI-EAG was then correlated with a combined outcome of major ventricular arrhythmia [sudden cardiac arrest, sustained ventricular tachycardia, and appropriate implantable cardioverter-defibrillator shocks], heart transplantation, and cardiovascular death.
Results: Overall, 147/1,049 (14%) patients with genetically-mediated ACM/DCM had a P/LP variant in LMNA. Of these, 80/147 (54%) LMNA variant-positive patients (52% female, mean chronological age 36 ± 15 years) had ECGs suitable for AI-EAG analysis. Most (52/80; 65%) had an AI-EAG >10 years with a mean AI-EAG of 17 ± 13 years. Of note, the AI-EAG was greater in those with a clinical cardiac phenotype (20 ± 14 vs. 13 ± 10 years; p = 0.011). As a continuous variable, an increased AI-EAG was associated with increased risk of the composite outcome at a median follow-up of 20 months (HR 1.036; 95% CI 1.004–1.068; p = 0.026) and AI-EAG > 10 and > 20 years were both associated with elevated risk (HR 4.272; 95% CI 1.388–13.147; p = 0.011 and HR 3.732; 95% CI 1.505–9.255; p = 0.004, respectively).
Conclusion: In cardiac laminopathy, an increased AI-EAG was common and correlated with adverse cardiovascular outcomes. Non-invasive ascertainment of electrocardiographic aging by AI may provide a novel prognostic marker in cardiac laminopathy. Future studies are needed to validate this finding and further define the role of the AI-EAG in the risk-stratification of patients with cardiac laminopathy.
  • Castrichini, Matteo  ( Mayo Clinic , Rochester , Minnesota , United States )
  • Sularz, Agata  ( Mayo Clinic , Rochester , Minnesota , United States )
  • Garmany, Ramin  ( Mayo Clinic , Rochester , Minnesota , United States )
  • Tester, David  ( MAYO CLINIC COLLEGE OF MEDICINE , Rochester , Minnesota , United States )
  • Bos, Johan  ( Mayo Clinic College of Medicine , Rochester , Minnesota , United States )
  • Attia, Zachi  ( Mayo Clinic , Rochester , Minnesota , United States )
  • Noseworthy, Peter  ( MAYO CLINIC , Rochester , Minnesota , United States )
  • Friedman, Paul  ( MAYO CLINIC , Rochester , Minnesota , United States )
  • Lopez-jimenez, Francisco  ( MAYO CLINIC COLL MEDICINE , Rochester , Minnesota , United States )
  • Ackerman, Michael  ( Mayo Clinic , Rochester , Minnesota , United States )
  • Milone, Margherita  ( Mayo Clinic , Rochester , Minnesota , United States )
  • Giudicessi, John  ( Mayo Clinic , Rochester , Minnesota , United States )
  • Author Disclosures:
    Matteo Castrichini: DO NOT have relevant financial relationships | Michael Ackerman: DO have relevant financial relationships ; Consultant:Abbott:Active (exists now) ; Royalties/Patent Beneficiary:UpToDate:Active (exists now) ; Royalties/Patent Beneficiary:Thryv Therapeutics:Active (exists now) ; Royalties/Patent Beneficiary:Solid Biosciences:Active (exists now) ; Royalties/Patent Beneficiary:Prolaio:Active (exists now) ; Royalties/Patent Beneficiary:ARMGO Pharma:Active (exists now) ; Royalties/Patent Beneficiary:AliveCor:Active (exists now) ; Consultant:Tenaya Therapeutics:Active (exists now) ; Consultant:Medtronic:Active (exists now) ; Consultant:Invitae:Past (completed) ; Consultant:Illumina:Active (exists now) ; Consultant:Bristol Myers Squibb:Past (completed) ; Consultant:Boston Scientific:Active (exists now) ; Consultant:BioMarin Pharmaceutical:Past (completed) | Margherita Milone: DO NOT have relevant financial relationships | John Giudicessi: DO have relevant financial relationships ; Consultant:Avidity Biosciences:Active (exists now) ; Consultant:Nuevocor Therapeutics:Active (exists now) ; Consultant:Citizen Health:Active (exists now) | Agata Sularz: DO NOT have relevant financial relationships | Ramin Garmany: DO NOT have relevant financial relationships | David Tester: No Answer | Johan Bos: DO NOT have relevant financial relationships | Zachi Attia: No Answer | Peter Noseworthy: DO have relevant financial relationships ; Royalties/Patent Beneficiary:Anumana:Active (exists now) | Paul Friedman: DO have relevant financial relationships ; Other (please indicate in the box next to the company name):Anumana:Active (exists now) ; Other (please indicate in the box next to the company name):Eko Health:Active (exists now) ; Other (please indicate in the box next to the company name):AliveCor:Active (exists now) | Francisco Lopez-Jimenez: DO have relevant financial relationships ; Advisor:Novo Nordisk:Active (exists now) ; Other (please indicate in the box next to the company name):Up-To-Date Author of chapter:Active (exists now) ; Consultant:Regeneron:Active (exists now) ; Advisor:WizeHealth:Past (completed) ; Royalties/Patent Beneficiary:Anumana:Active (exists now) ; Consultant:New Amsterdam Pharma:Past (completed) ; Consultant:MediWhale:Past (completed) ; Researcher:Select Research:Past (completed) ; Consultant:K-Health:Active (exists now) ; Consultant:Kento Health:Active (exists now) ; Advisor:Anumana:Active (exists now)
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Predicting and Treating Genetic Cardiomyopathies

Sunday, 11/09/2025 , 11:30AM - 12:30PM

Abstract Poster Board Session

More abstracts on this topic:
A DHX38 Spliceosomal Mutation Impairs MYC Signaling, Cardiac Transcriptome Splicing, and Leads to Diastolic Dysfunction

Iwanski Jessika, Sarvagalla Sailu, Methawasin Mei, Van Den Berg Marloes, Churko Jared

A New Biomarker of Aging Derived From Electrocardiogram Improves Risk Prediction of Incident Myocardial Infarction and Stroke.

Wilsgaard Tom, Rosamond Wayne, Schirmer Henrik, Lindekleiv Haakon, Attia Zachi, Lopez-jimenez Francisco, Leon David, Iakunchykova Olena

More abstracts from these authors:
Prevalence, Clinical Characteristics, and Outcomes of Patients with Genotype-Positive Arrhythmogenic Cardiomyopathy Presenting with a Sentinel Sudden Cardiac Arrest

Swain William, Garmany Ramin, Castrichini Matteo, Bos Johan, Neves Raquel, Ackerman Michael, Giudicessi John

Electrocardiographic Aging in Genetic Cardiomyopathies: Insights from an Artificial Intelligence-Enabled Electrocardiogram Analysis

Sularz Agata, Ackerman Michael, Giudicessi John, Castrichini Matteo, Garmany Ramin, Bos Johan, Attia Zachi, Noseworthy Peter, Friedman Paul, Lopez-jimenez Francisco, Milone Margherita

You have to be authorized to contact abstract author. Please, Login
Not Available